VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Enbridge Inc. vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Enbridge Inc.
ENB · Toronto Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Enbridge Inc.'s moat claims, evidence, and risks.
View ENB analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Enbridge Inc. leads (92 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: Enbridge Inc. has 4 segments (72.8% in Liquids Pipelines); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Moat breadth: Enbridge Inc. has 6 moat types across 3 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
Enbridge Inc.
Liquids Pipelines
Crude oil & liquids pipeline transportation plus terminals/storage
North America (Canada & U.S.)
Producers, refiners, marketers (shippers)
Midstream pipeline operator
72.8%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
Enbridge Inc. strengths
Gilead Sciences, Inc. strengths
Segment mix
Enbridge Inc. segments
Full profile >Liquids Pipelines
Oligopoly
Gas Transmission and Midstream
Oligopoly
Gas Distribution and Storage
Monopoly
Renewable Power Generation
Competitive
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.